Business
Universal Ibogaine Announces Engagement of Investor Relations Advisor
(TheNewswire) Calgary, AB – TheNewsire - October 21, 2021 ...
About this update from Universal Ibogaine Inc
[{"type":"text","content":"Universal Ibogaine Announces Engagement of Investor Relations Advisor\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n Calgary, AB –\n \n \n TheNewsire -\n \n \n October 21, 2021 –\n \n \n Universal Ibogaine Inc. (\n \n \n TSXV:IBO\n \n \n ) (\n \n \n “UI” or the “Company”\n \n \n ), a life sciences company with a mission to research and\ndeliver medicalized ibogaine-centered addiction care, advises that it\nhas retained\n \n \n Volume Hunters Ltd. (\n \n \n “Volume Hunters”\n \n \n )\nof Vancouver, Canada, as an enhancement of its’ investor relations\nprogram.\n \n \n \n \n IR and Marketing Engagements\n \n \n \n \n Volume Hunters will provide social media and capital\nmarkets advisory services to support the distribution of the UI story\nacross multiple social media channels.  The expected result is\nincreased awareness of UI’s  plans for research into utilizing\nibogaine as part of the delivery of a continuum of care treating\nopioid abuse and other addictions.\n \n \n \n \n The contract is for $50,000 paid for services provided\nover a 12-month period, and is subject to approval of the TSX Venture\nExchange (the “\n \n \n TSXV\n \n \n ”).\n \n \n \n \n Dr. Rami Batal, UI’s Chief Executive Officer, noted\n“we are pleased have access to Volume Hunters expertise, as their\n \n \n mandate will focus on increasing UI’s\nvisibility and building long term relationships with institutional and\nhigh net worth investors.\n \n \n ”\n \n \n \n \n Maturity date of Promissory Notes\nPayable\n \n \n \n \n UI also advises that its’ prior news release of\nOctober 4, 2021 inadvertently referred to the maturity date of\n$350,000 of convertible promissory notes payable as having been\nextended to February 28, 2021, which should have instead read February\n28, 2022.  TSXV approval of the extension of the maturity date to\nFebruary 28, 2022 has been received.\n \n \n \n \n About Universal Ibogaine Inc.\n \n \n \n \n UI is a life sciences company with the goal of\nclinically developing ibogaine, a natural plant substance, as a\nprescribed addiction interruption medicine for the treatment of Opioid\nUse Disorder.  An application to Health Canada is being developed to\nundertake clinical trials aimed at p...